Content validity and clinical meaningfulness of the HFMSE in spinal muscular atrophy

BMC Neurology

Volumn 17, Issue 1, 2017, Pages

  Pera, Maria C ^a   Coratti, Giorgia ^a   Forcina, Nicola ^a   Mazzone, Elena S ^a   Scoto, Mariacristina ^b   Montes, Jacqueline ^c   Pasternak, Amy ^d   Mayhew, Anna ^e   Messina, Sonia ^f   Sframeli, Maria ^f   Main, Marion ^b   Lofra, Robert Muni ^e   Duong, Tina ^g   Ramsey, Danielle ^b   Dunaway, Sally ^c   Salazar, Rachel ^c   Fanelli, Lavinia ^a   Civitello, Matthew ^h   de Sanctis, Roberto ^a   Antonaci, Laura ^a   Lapenta, Leonardo ^a   Lucibello, Simona ^a   Pane, Marika ^a   Day, John ^g   Darras, Basil T ^d   De Vivo, Darryl C ^c   Muntoni, Francesco ^b   Finkel, Richard ^h   Mercuri, Eugenio ^a   more..

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

^e NEWCASTLE UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF MESSINA   (Italy)

^g STANFORD UNIVERSITY   (United States)

^h UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Carers; Clinical trials; Quality of life; Spinal muscular atrophy

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CAREGIVER; CLINICAL ARTICLE; CONTENT VALIDITY; DAILY LIFE ACTIVITY; DETERIORATION; FUNCTIONAL STATUS; HAMMERSMITH FUNCTIONAL MOTOR SCALE EXPANDED; HEALTH PRACTITIONER; HUMAN; INFORMATION PROCESSING; NEUROLOGIC DISEASE ASSESSMENT; OUTCOME ASSESSMENT; QUESTIONNAIRE; SPINAL MUSCULAR ATROPHY; CHILD; FEMALE; HEREDITARY SPINAL MUSCULAR ATROPHY; MALE; PATIENT; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; VALIDATION STUDY; YOUNG ADULT;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; CAREGIVERS; CHILD; FEMALE; FOCUS GROUPS; HUMANS; MALE; MUSCULAR ATROPHY, SPINAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENTS; SEVERITY OF ILLNESS INDEX; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD; YOUNG ADULT;

EID: 85013743931     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-017-0790-9     Document Type: Article

References (18)

1. Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. Eur J Paediatr Neurol. 2003;7(4):155-9.
2. O'Hagen JM, Glanzman AM, McDermott MP, Ryan PA, Flickinger J, Quigley J, Riley S, Sanborn E, Irvine C, Martens WB, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. Neuromuscul Disord. 2007;17(9-10):693-7.
3. Mercuri E, Messina S, Battini R, Berardinelli A, Boffi P, Bono R, Bruno C, Carboni N, Cini C, Colitto F, et al. Reliability of the Hammersmith functional motor scale for spinal muscular atrophy in a multicentric study. Neuromuscul Disord. 2006;16(2):93-8.
4. Mercuri E, Mayhew A, Muntoni F, Messina S, Straub V, Van Ommen GJ, Voit T, Bertini E, Bushby K. Towards harmonisation of outcome measures for DMD and SMA within TREAT-NMD; report of three expert workshops: TREAT-NMD/ENMC workshop on outcome measures, 12th--13th May 2007, Naarden, The Netherlands; TREAT-NMD workshop on outcome measures in experimental trials for DMD, 30th June--1st July 2007, Naarden, The Netherlands; conjoint Institute of Myology TREAT-NMD meeting on physical activity monitoring in neuromuscular disorders, 11th July 2007, Paris, France. Neuromuscul Disord. 2008;18(11):894-903.
5. Finkel R, Bertini E, Muntoni F, Mercuri E, Group ESWS. 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7-9 November 2014, Heemskerk. The Netherlands. Neuromuscul Disord. 2015;25(7):593-602.
6. Kayadjanian N, Burghes A, Finkel RS, Mercuri E, Rouault F, Schwersenz I, Talbot K. SMA-EUROPE workshop report: Opportunities and challenges in developing clinical trials for spinal muscular atrophy in Europe. Orphanet J Rare Dis. 2013;8:44.
7. Montes J, Glanzman AM, Mazzone ES, Martens WB, Dunaway S, Pasternak A, Riley SO, Quigley J, Pandya S, De Vivo DC, et al. Spinal muscular atrophy functional composite score: A functional measure in spinal muscular atrophy. Muscle Nerve. 2015;52(6):942-7.
8. Kaufmann P, McDermott MP, Darras BT, Finkel R, Kang P, Oskoui M, Constantinescu A, Sproule DM, Foley AR, Yang M, et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch Neurol. 2011;68(6):779-86.
9. Kaufmann P, McDermott MP, Darras BT, Finkel RS, Sproule DM, Kang PB, Oskoui M, Constantinescu A, Gooch CL, Foley AR, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79(18):1889-97.
10. Mercuri E, Finkel R, Montes J, Mazzone ES, Sormani MP, Main M, Ramsey D, Mayhew A, Glanzman AM, Dunaway S, et al. Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscul Disord. 2016;26(2):126-31.
11. Kissel JT, Scott CB, Reyna SP, Crawford TO, Simard LR, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, et al. SMA CARNIVAL TRIAL PART II: a prospective, single-armed trial of L-carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PLoS One. 2011;6(7):e21296.
12. Swoboda KJ, Scott CB, Crawford TO, Simard LR, Reyna SP, Krosschell KJ, Acsadi G, Elsheik B, Schroth MK, D'Anjou G, et al. SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. PLoS One. 2010;5(8):e12140.
13. Mercuri E, Bertini E, Messina S, Pelliccioni M, D'Amico A, Colitto F, Mirabella M, Tiziano FD, Vitali T, Angelozzi C, et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord. 2004;14(2):130-5.
14. Mercuri E, Bertini E, Messina S, Solari A, D'Amico A, Angelozzi C, Battini R, Berardinelli A, Boffi P, Bruno C, et al. Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology. 2007;68(1):51-5.
15. Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, Norris DA, Bennett CF, Bishop KM. Results from a phase 1 study of nusinersen (ISIS-SMN (Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890-7.
16. U. S. Department of Health and Human Services. Guidance for Industry Use in Medical Product Development to Support Labeling Claims Guidance for Industry. 2009.
17. Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study. BMC Neurol. 2015;15:217.
18. R. USDoHaHSFaDfDa. Guidance for Industry Use in Medical Product Development to Support Labeling Claims Guidance for Industry. 2009.